Working to transform cancer care through early detection

Despite decades of effort, and tests that screen for five cancers in the U.S., cancer is projected to become the world’s leading killer in 2021.

That’s why GRAIL is pioneering Galleri™, a multi-cancer early detection test that can detect over 50 types of cancers — over 45 of which lack recommended screening today — with a low false positive rate, through a single blood draw.

We believe we have the potential to transform cancer care by reducing cancer deaths and decreasing healthcare costs by detecting more cancers earlier.

Learn More About Galleri
Who we are

GRAIL is a healthcare company in pursuit of innovation to solve medicine’s most important challenges. Our team of leading scientists, engineers, and clinicians are on an urgent mission to detect more cancers early, when they are more treatable and potentially curable.

Learn About Us

Our scientific approach

We are developing new technologies for early detection using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science. This rigorous approach is what we believe it takes to transform cancer care.

Learn About Our Approach